{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:41Z","timestamp":1792815221575,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.blre.2020.100709","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T19:16:10Z","timestamp":1590261370000},"page":"100709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1\/PD-L1 and CTLA-4 pathways"],"prefix":"10.1016","volume":"45","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100709_bb0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"10.1016\/j.blre.2020.100709_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100709_bb0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100709_bb0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100709_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737140.2019.1589374","article-title":"Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled","volume":"19","author":"Bewersdorf","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2020.100709_bb0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0045","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0050","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2020.100709_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets","volume":"21","author":"Stahl","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2020.100709_bb0060","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100709_bb0065","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2020.100709_bb0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100709_bb0075","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0080","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti\u2013programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-016-2153-5","article-title":"Bone marrow T-cell percentage: a novel prognostic indicator in acute myeloid leukemia","volume":"105","author":"Ismail","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2020.100709_bb0100","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0105","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100709_bb0110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2020.100709_bb0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","article-title":"T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment","volume":"8","author":"Schnorfeil","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100709_bb0125","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0130","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100709_bb0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0140","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood-2019-129455","article-title":"LAG3 inhibition decreases AML-induced immunosuppression and improves T cell-mediated killing","volume":"134","author":"Abdelhakim","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2018\/2458679","article-title":"The rising era of immune checkpoint inhibitors in myelodysplastic syndromes","volume":"2018","author":"Chokr","year":"2018","journal-title":"Adv Hematol"},{"key":"10.1016\/j.blre.2020.100709_bb0150","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fonc.2018.00444","article-title":"Acute myeloid leukemia and the bone marrow niche-take a closer look","volume":"8","author":"Behrmann","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/bloodadvances.2019000792","article-title":"Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival","volume":"4","author":"Br\u00fcck","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100709_bb0160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2020.100709_bb0165","first-page":"423","article-title":"Immune Checkpoint profiling of TP53 mutant and wild-type myeloid malignancies: TP53 mutations direct immune tolerance via an immunosuppressive phenotype","volume":"130","author":"Sallman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0170","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0175","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of Ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100709_bb0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V128.22.345.345","article-title":"Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0185","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100709_bb0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0195","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/bmt.2017.78","article-title":"Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation","volume":"52","author":"Gros","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100709_bb0200","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity."},{"key":"10.1016\/j.blre.2020.100709_bb0205","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2020.100709_bb0210","doi-asserted-by":"crossref","DOI":"10.1177\/2040620718816698","article-title":"Epigenetic therapy combinations in acute myeloid leukemia: what are the options?","volume":"10","author":"Bewersdorf","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2020.100709_bb0215","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100709_bb0220","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/15592294.2015.1017198","article-title":"Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts","volume":"10","author":"Srivastava","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.blre.2020.100709_bb0225","article-title":"Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100709_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081660","article-title":"Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment","volume":"18","author":"Gbolahan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2020.100709_bb0235","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100709_bb0240","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0250","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2018-99-115097","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"132","author":"Lindblad","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0255","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2019-131494","article-title":"Azacitidine (AZA) with nivolumab (Nivo), and AZA with nivo + ipilimumab (Ipi) in relapsed\/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0260","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1182\/blood-2019-129598","article-title":"Updated preliminary results from a phase II study combining azacitidine and pembrolizumab in patients with higher-risk myelodysplastic syndrome","volume":"134","author":"Chien","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0265","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","article-title":"How I treat MDS after hypomethylating agent failure","volume":"133","author":"Santini","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0270","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2019-122896","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2020.100709_bb0280","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.leu.2403391","article-title":"Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells","volume":"18","author":"Vereecque","year":"2004","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100709_bb0285","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2019-126065","article-title":"Final clinical results of a phase II study of high dose cytarabine followed by pembrolizumab in relapsed\/refractory AML","volume":"134","author":"Zeidner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100709_bb0295","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2018-99-116078","article-title":"Results of a phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"132","author":"Assi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0300","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.leukres.2014.03.018","article-title":"Elevated TIM3+ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis","volume":"38","author":"J-l","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100709_bb0305","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100709_bb0310","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0315","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2020.100709_bb0320","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100709_bb0325","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2020.100709_bb0330","first-page":"72","article-title":"TIM3 expression by leukemic and non-leukemic myeloblasts","volume":"84","author":"Roth","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2020.100709_bb0335","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2020.100709_bb0340","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2019-128178","article-title":"Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0345","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1182\/blood-2019-127041","article-title":"A randomized, double-blind, placebo-controlled, phase II study of MBG453 added to hypomethylating agents (HMAs) in patients (pts) with intermediate, high, or very high risk myelodysplastic syndrome (MDS): stimulus-MDS1","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100709_bb0350","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bi-specific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100709_bb0355","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2020.100709_bb0360","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2018.00385","article-title":"Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells","volume":"9","author":"Lichtenegger","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0365","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2020.100709_bb0370","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2020.100709_bb0375","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0380","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100709_bb0385","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.blre.2020.100709_bb0390","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2019-127474","article-title":"Phase 1\u20132 study of pembrolizumab combined with the anti-LAG-3 antibody MK-4280 for the treatment of hematologic malignancies","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0395","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11095","article-title":"Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development","volume":"485","author":"Zheng","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.blre.2020.100709_bb0400","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","article-title":"LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells","volume":"17","author":"Li","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0405","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100709_bb0410","first-page":"1","article-title":"LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents","author":"Chien","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100709_bb0415","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","article-title":"Disrupting LILRB4\/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development","volume":"7","author":"Gui","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2020.100709_bb0420","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2020.100709_bb0425","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fonc.2015.00083","article-title":"Targeting the innate immune system as immunotherapy for acute myeloid leukemia","volume":"5","author":"Curran","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era?","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2020.100709_bb0435","doi-asserted-by":"crossref","first-page":"11284","DOI":"10.18632\/oncotarget.14500","article-title":"SIRPalpha-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells","volume":"8","author":"Ponce","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2020.100709_bb0440","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100709_bb0445","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s12094-016-1489-x","article-title":"CD47: a potential immunotherapy target for eliminating cancer cells","volume":"18","author":"Kong","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0450","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0455","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRPalpha in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2020.100709_bb0460","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100709_bb0465","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell."},{"key":"10.1016\/j.blre.2020.100709_bb0470","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100709_bb0475","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2020.100709_bb0480","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1074\/jbc.272.2.1323","article-title":"Stimulation of platelet activation and aggregation by a carboxyl-terminal peptide from thrombospondin binding to the integrin-associated protein receptor","volume":"272","author":"Dorahy","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2020.100709_bb0485","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.7","article-title":"Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies","volume":"7","author":"Pietsch","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100709_bb0490","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0495","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2018.36.15_suppl.7504","article-title":"Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed\/refractory non-Hodgkin lymphoma: Initial phase 1b\/2 results","volume":"36","author":"Advani","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0500","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-Class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0505","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2019-125363","article-title":"A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory (R\/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): final results","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0510","article-title":"TTI-621 (SIRPalphaFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100709_bb0515","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100709_bb0520","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2019-131018","article-title":"Sirp\u03b1fc treatment targets human acute myeloid leukemia stem cells","volume":"134","author":"Galkin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0525","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/ni1174","article-title":"Immune activation modulates hematopoiesis through interactions between CD27 and CD70","volume":"6","author":"Nolte","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0530","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100709_bb0535","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood-2016-12-756585","article-title":"CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies","volume":"130","author":"Al Sayed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0540","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ni869","article-title":"Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions","volume":"4","author":"Tesselaar","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0545","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood-2019-129916","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in humans","volume":"134","author":"Ochsenbein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0555","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/2326-6066.CIR-17-0212","article-title":"The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia","volume":"6","author":"Nuebling","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2020.100709_bb0560","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2141.2003.04791.x","article-title":"Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity","volume":"124","author":"Yanagita","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100709_bb0565","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 agonists and combination immunotherapy: putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0570","article-title":"The minimal that kills: why defining and targeting measurable residual disease is the \u201csine qua non\u201d for further progress in management of acute myeloid leukemia","volume":"100650","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2020.100709_bb0575","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0580","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0585","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0590","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-020-02490-2","article-title":"Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition","volume":"69","author":"Greiner","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2020.100709_bb0595","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2019.01.013","article-title":"Monitoring TIGIT\/DNAM-1 and PVR\/PVRL2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia","volume":"25","author":"Hattori","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100709_bb0600","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post\u2013allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0605","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0610","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2018.07.010","article-title":"Biomarkers of response to immune checkpoint blockade in cancer treatment","volume":"130","author":"Fujii","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2020.100709_bb0615","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0620","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100709_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.08.014","article-title":"Prospective isolation and characterization of genetically and functionally distinct AML subclones","volume":"34","author":"de Boer","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100709_bb0630","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100709_bb0635","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0640","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-LB-222","article-title":"Polyfunctionality determined by single-cell proteomics of bone marrow-derived CD4 T cells from patients with acute myeloid leukemia identifies patients responding to anti-PD-1-based therapy and discovers profound T cell defect in mutant TP53 disease","volume":"79","author":"Daver","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2020.100709_bb0645","first-page":"JCO1901823","article-title":"Integrating the \u201cimmunome\u201d in the stratification of myelodysplastic syndromes and future clinical trial design","author":"Winter","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0650","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/17474086.2019.1592673","article-title":"Getting personal with myelodysplastic syndromes: is now the right time?","volume":"12","author":"Chokr","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100709_bb0655","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cyto.b.21860","article-title":"Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation","volume":"98","author":"Behbehani","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2020.100709_bb0660","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100709_bb0665","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1085146","article-title":"PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity","volume":"5","author":"Lim","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.blre.2020.100709_bb0670","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.4049\/jimmunol.1100274","article-title":"Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer","volume":"186","author":"Krempski","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0675","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","article-title":"Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer","volume":"9","author":"Versteven","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2020.100709_bb0680","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0685","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100709_bb0690","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100709_bb0695","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2030059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2030059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:26:29Z","timestamp":1759436789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2030059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":138,"alternative-id":["S0268960X2030059X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100709","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1\/PD-L1 and CTLA-4 pathways","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100709"}}